FOXA1
Forkhead box protein A1 (FOXA1), also known as hepatocyte nuclear factor 3-alpha (HNF-3A), is a protein that in humans is encoded by the FOXA1 gene.[1][2][3]
Contents |
[edit] Function
FOXA1 is a member of the forkhead class of DNA-binding proteins. These hepatocyte nuclear factors are transcriptional activators for liver-specific transcripts such as albumin and transthyretin, and they also interact with chromatin. Similar family members in mice have roles in the regulation of metabolism and in the differentiation of the pancreas and liver.[1]
[edit] Marker in breast cancer
FOXA1 in breast cancer is highly correlated with ERα+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 absence in ERα+ cancer might identify ERα+ cancers that are resistant to endocrine therapy. In ERα– breast cancer FOXA1 is highly correlated with improved disease free survival and GATA3. FOXA1 is a downstream target of GATA3 in the mammary gland. [4] Expression in ERα– cancers may identify a subset of tumors that is responsive to other endocrine therapies such as androgen receptor antagonist treatment.[5][6]
[edit] Role in prostate cancer
Mutations in this gene have been recurrently seen in instances of prostate cancer.[7]
[edit] References
- ^ a b "Entrez Gene: forkhead box A1". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3169.
- ^ Bingle CD, Gowan S (1996). "Molecular cloning of the forkhead transcription factor HNF-3 alpha from a human pulmonary adenocarcinoma cell line.". Biochim Biophys Acta 1307 (1): 17–20. PMID 8652662.
- ^ Mincheva A, Lichter P, Schütz G, Kaestner KH (1997). "Assignment of the human genes for hepatocyte nuclear factor 3-alpha, -beta, and -gamma (HNF3A, HNF3B, HNF3G) to 14q12-q13, 20p11, and 19q13.2-q13.4.". Genomics 39 (3): 417–9. doi:10.1006/geno.1996.4477. PMID 9119385.
- ^ Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z (December 2006). "GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland". Cell 127 (5): 1041–55. doi:10.1016/j.cell.2006.09.048. PMC 2646406. PMID 17129787.
- ^ Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F (2009). "Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumours". Breast Cancer Research 11 (3): R40. doi:10.1186/bcr2327. PMC 2716509. PMID 19549328.
- ^ Sanga S, Broom BM, Cristini V, Edgerton ME (2009). "Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family". BMC Medical Genomics 2: 59. doi:10.1186/1755-8794-2-59. PMC 2753593. PMID 19747394.
- ^ Barbieri, C. E.; Baca, S. C.; Lawrence, M. S.; Demichelis, F.; Blattner, M.; Theurillat, J. P.; White, T. A.; Stojanov, P. et al. (2012). "Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer". Nature Genetics 44 (6): 685. doi:10.1038/ng.2279.
[edit] Further reading
- Song L, Xu Z, Zhang C, et al. (2009). "Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line.". Biochem. Biophys. Res. Commun. 386 (1): 30–4. doi:10.1016/j.bbrc.2009.05.120. PMID 19486887.
- Zhang Y, Ali TZ, Zhou H, et al. (2010). "ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer.". Cancer Res. 70 (1): 240–8. doi:10.1158/0008-5472.CAN-09-2904. PMID 20048076.
- McMullin RP, Dobi A, Mutton LN, et al. (2010). "A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland.". Proc. Natl. Acad. Sci. U.S.A. 107 (1): 98–103. doi:10.1073/pnas.0902001107. PMID 20018680.
- Sun Q, Yu X, Degraff DJ, Matusik RJ (2009). "Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression.". Mol. Endocrinol. 23 (12): 2038–47. doi:10.1210/me.2009-0092. PMID 19846536.
- Liu N, Niu Y, Wang SL, et al. (2010). "[Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas]". Zhonghua Yi Xue Za Zhi 90 (20): 1403–7. PMID 20646630.
- Haiman CA, Garcia RR, Hsu C, et al. (2009). "Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.". BMC Cancer 9: 43. doi:10.1186/1471-2407-9-43. PMC 2637888. PMID 19183483.
- Kohler S, Cirillo LA (2010). "Stable chromatin binding prevents FoxA acetylation, preserving FoxA chromatin remodeling.". J. Biol. Chem. 285 (1): 464–72. doi:10.1074/jbc.M109.063149. PMID 19897491.
- Malik S, Jiang S, Garee JP, et al. (2010). "Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM.". Mol. Cell. Biol. 30 (2): 399–412. doi:10.1128/MCB.00907-09. PMID 19917725.
- Motallebipour M, Ameur A, Reddy Bysani MS, et al. (2009). "Differential binding and co-binding pattern of FOXA1 and FOXA3 and their relation to H3K4me3 in HepG2 cells revealed by ChIP-seq.". Genome Biol. 10 (11): R129. doi:10.1186/gb-2009-10-11-r129. PMID 19919681.
- Eeckhoute J, Lupien M, Meyer CA, et al. (2009). "Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers.". Genome Res. 19 (3): 372–80. doi:10.1101/gr.084582.108. PMID 19129543.
- Nakshatri H, Badve S (2007). "FOXA1 as a therapeutic target for breast cancer.". Expert Opin. Ther. Targets 11 (4): 507–14. doi:10.1517/14728222.11.4.507. PMID 17373880.
- Iacobazzi V, Infantino V, Bisaccia F, et al. (2009). "Role of FOXA in mitochondrial citrate carrier gene expression and insulin secretion.". Biochem. Biophys. Res. Commun. 385 (2): 220–4. doi:10.1016/j.bbrc.2009.05.030. PMID 19445897.
- Nucera C, Eeckhoute J, Finn S, et al. (2009). "FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.". Clin. Cancer Res. 15 (11): 3680–9. doi:10.1158/1078-0432.CCR-08-3155. PMID 19470727.
- Nakshatri H, Badve S (2009). "FOXA1 in breast cancer.". Expert Rev Mol Med 11: e8. doi:10.1017/S1462399409001008. PMID 19261198.
- Song Y, Washington MK, Crawford HC (2010). "Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer.". Cancer Res. 70 (5): 2115–25. doi:10.1158/0008-5472.CAN-09-2979. PMID 20160041.
- Lee HJ, Chattopadhyay S, Yoon WH, et al. (2010). "Overexpression of hepatocyte nuclear factor-3alpha induces apoptosis through the upregulation and accumulation of cytoplasmic p53 in prostate cancer cells.". Prostate 70 (4): 353–61. doi:10.1002/pros.21069. PMID 19866472.
- Bernardo GM, Lozada KL, Miedler JD, et al. (2010). "FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.". Development 137 (12): 2045–54. doi:10.1242/dev.043299. PMID 20501593.
- Albergaria A, Paredes J, Sousa B, et al. (2009). "Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.". Breast Cancer Res. 11 (3): R40. doi:10.1186/bcr2327. PMC 2716509. PMID 19549328.
- Huang QY, Li GH, Kung AW (2009). "The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis.". Bone 45 (2): 289–94. doi:10.1016/j.bone.2009.03.676. PMID 19371798.
- Sano M, Aoyagi K, Takahashi H, et al. (2010). "Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis.". Int. J. Oncol. 36 (2): 321–30. PMID 20043065.
[edit] External links
| This article on a gene on chromosome 14 is a stub. You can help Wikipedia by expanding it. |
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
|

